Rocket Pharmaceuticals
RCKT
186 hedge funds and large institutions have $2.48B invested in Rocket Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 70 increasing their positions, 62 reducing their positions, and 26 closing their positions.
475% more call options, than puts
Call options by funds: $20.7M | Put options by funds: $3.6M
13% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 62
3.34% more ownership
Funds ownership: 98.72% → 102.06% (+3.3%)
4% less funds holding
Funds holding: 194 → 186 (-8)
7% less capital invested
Capital invested by funds: $2.67B → $2.48B (-$183M)
27% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 26
38% less funds holding in top 10
Funds holding in top 10: 8 → 5 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$47M |
| 2 |
State Street
Boston,
Massachusetts
|
+$27.3M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$27.2M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$22.6M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$13.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$19.7M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$17.7M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$8M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$5.18M |
| 5 |
Goldman Sachs
New York
|
-$4.65M |
RCKT Hedge Fund Activity: Q1 2024 in Review
186 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q1 2024, worth a combined $2.48B — down 6.9% from $2.67B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of RCKT and 19 opened new positions — a net loss of 7 holders — while 62 trimmed existing stakes and 70 added.
The largest buyer was Janus Henderson Group, adding an estimated $47M. The largest seller was Avidity Partners Management, cutting an estimated $19.7M.
- 186 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q1 2024, down from 194 in Q4 2023.
- Funds reported $2.48B of Rocket Pharmaceuticals stock for Q1 2024, down 6.9% quarter-over-quarter.
- 19 funds opened new Rocket Pharmaceuticals positions in Q1 2024 and 26 closed out, a net change of -7 holders.
- The largest Rocket Pharmaceuticals buyer in Q1 2024 was Janus Henderson Group, an estimated $47M added.
- The largest Rocket Pharmaceuticals seller in Q1 2024 was Avidity Partners Management, an estimated $19.7M sold.
Based on aggregated 13F filings for Q1 2024.